$1.31
9.03%
Nasdaq, Fri, Nov 15 2024
ISIN
US81362J1007
Symbol
EYES

Second Sight Medical Products, Inc. Stock price

$1.31
+0.15 12.93% 1M
-0.60 31.41% 6M
+0.29 28.43% YTD
+0.36 37.89% 1Y
-6.85 83.95% 3Y
-19.92 93.83% 5Y
-477.97 99.73% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.13 9.03%
ISIN
US81362J1007
Symbol
EYES
Sector

Key metrics

Market capitalization $72.39m
Enterprise Value $72.80m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.95
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-24.43m
Free Cash Flow (TTM) Free Cash Flow $-19.46m
Cash position $19.65m
EPS (TTM) EPS $-0.44
P/E forward negative
Short interest 3.85%
Show more

Is Second Sight Medical Products, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Second Sight Medical Products, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Second Sight Medical Products, Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Second Sight Medical Products, Inc. forecast:

Buy
100%

Financial data from Second Sight Medical Products, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.41 0.41
11% 11%
-
-0.41 -0.41
11% 11%
-
- Selling and Administrative Expenses 7.47 7.47
33% 33%
-
- Research and Development Expense 16 16
3% 3%
-
-24 -24
15% 15%
-
- Depreciation and Amortization 0.41 0.41
11% 11%
-
EBIT (Operating Income) EBIT -24 -24
14% 14%
-
Net Profit -23 -23
13% 13%
-

In millions USD.

Don't miss a Thing! We will send you all news about Second Sight Medical Products, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Second Sight Medical Products, Inc. engages in the development, manufacture, and marketing of implantable visual prosthetics. It operates through the following geographical segments: United States, Italy, France, and China. The firm's product include Argus II Retinal Prosthesis System that treats outer retinal degenerations, such as retinitis pigmentosa, also referred to as RP. The company was founded by Alfred E. Mann, Aaron Mendelsohn, Sam Williams, Robert J. Greenberg, and Gunnar Bjorg in 1998 and is headquartered in Sylmar, CA.

Head office United States
CEO Adam Mendelsohn
Employees 44
Founded 2003
Website www.vivani.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today